Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Hewlett Packard Enterprise Co (HPE) Price & Performance

Charles River Laboratories Intl. IncTrade
Hewlett Packard Enterprise CoTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Hewlett Packard Enterprise Co — how do they compare? Charles River Laboratories Intl. Inc trades at $227.5 (market cap $11.14B), while Hewlett Packard Enterprise Co trades at $46.32 (market cap $65.63B). The key difference: Hewlett Packard Enterprise Co is far larger — about 5.9× Charles River Laboratories Intl. Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.15% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLHPE
Market Cap
$11.14B$65.63B
Sector
HealthTechnology
52-Week High
$233.60$56.14
52-Week Low
$145.57$19.81
Enterprise Value
$14.00B$81.58B
Dividend Yield
1.15%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Hewlett Packard Enterprise Co

HPE trades at $47.24, down 2.61% on the day, with a bullish technical signal from moving averages. Recent earnings beats and a consensus price target of $69.69 suggest upside potential. The company reported revenue of $34.30B in 2025, though net income fell sharply to $57M. Strong AI infrastructure demand and a nearly $6B backlog, as noted by The Motley Fool on July 9, 2026, highlight growth catalysts.

Outlook is positive with AI-driven demand boosting revenue projections to $38.8B in 2026. Risks include high debt-to-asset ratio of 29.48% in 2025 and margin pressures. Analysts are mixed with 46% buy ratings, indicating cautious optimism for long-term investors amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.

Read more on HPE